Cargando…
Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
BACKGROUND: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term “cancer” sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word “cancer,” the term noninvasive follicular thyroid neoplasm with pa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543635/ https://www.ncbi.nlm.nih.gov/pubmed/31146753 http://dx.doi.org/10.1186/s12957-019-1638-0 |
_version_ | 1783423118247723008 |
---|---|
author | Kaliszewski, Krzysztof Diakowska, Dorota Wojtczak, Beata Forkasiewicz, Zdzisław Pupka, Dominika Nowak, Łukasz Rudnicki, Jerzy |
author_facet | Kaliszewski, Krzysztof Diakowska, Dorota Wojtczak, Beata Forkasiewicz, Zdzisław Pupka, Dominika Nowak, Łukasz Rudnicki, Jerzy |
author_sort | Kaliszewski, Krzysztof |
collection | PubMed |
description | BACKGROUND: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term “cancer” sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word “cancer,” the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced. However, not all PTMCs can be classified as NIFTP. Sometimes, very aggressive PTMC cases might be observed. Some authors suggest that one of the risk factors for poor prognosis is lymph node metastasis. The aim of the study was to evaluate some clinicopathological features of PTMC as the risk factors for lymph node metastasis. MATERIAL AND METHODS: We performed a retrospective chart review and selected 177 patients with PTMC. To analyze the cases with potentially aggressive behavior, we enrolled PTMC patients with lymph node metastases (pN1, central, and/or lateral) and evaluated some of their clinicopathological features. RESULTS: The logistic regression analysis results demonstrated significantly higher rates of multifocal or bilateral tumor occurrence in the PTMC patients with pN1 than in the patients with pN0 (P < 0.0001 for both). In addition, the occurrence of thyroid tumors with sizes above 0.5 cm was a significant risk factor for lymph node metastasis (P < 0.0001). The results of the ROC analyses showed that the presence of multifocal or bilateral tumors and tumor sizes above 0.5 cm were significant predictors of lymph node metastasis (P < 0.0001 for all). CONCLUSIONS: Multifocal and bilateral PTMC tumors with diameters above 0.5 cm should be treated aggressively as “true cancer” and might benefit from lymph node dissection. Unifocal PTMC tumors with diameters equal to or below 0.5 cm may be treated less aggressively. |
format | Online Article Text |
id | pubmed-6543635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65436352019-06-04 Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? Kaliszewski, Krzysztof Diakowska, Dorota Wojtczak, Beata Forkasiewicz, Zdzisław Pupka, Dominika Nowak, Łukasz Rudnicki, Jerzy World J Surg Oncol Research BACKGROUND: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term “cancer” sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word “cancer,” the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced. However, not all PTMCs can be classified as NIFTP. Sometimes, very aggressive PTMC cases might be observed. Some authors suggest that one of the risk factors for poor prognosis is lymph node metastasis. The aim of the study was to evaluate some clinicopathological features of PTMC as the risk factors for lymph node metastasis. MATERIAL AND METHODS: We performed a retrospective chart review and selected 177 patients with PTMC. To analyze the cases with potentially aggressive behavior, we enrolled PTMC patients with lymph node metastases (pN1, central, and/or lateral) and evaluated some of their clinicopathological features. RESULTS: The logistic regression analysis results demonstrated significantly higher rates of multifocal or bilateral tumor occurrence in the PTMC patients with pN1 than in the patients with pN0 (P < 0.0001 for both). In addition, the occurrence of thyroid tumors with sizes above 0.5 cm was a significant risk factor for lymph node metastasis (P < 0.0001). The results of the ROC analyses showed that the presence of multifocal or bilateral tumors and tumor sizes above 0.5 cm were significant predictors of lymph node metastasis (P < 0.0001 for all). CONCLUSIONS: Multifocal and bilateral PTMC tumors with diameters above 0.5 cm should be treated aggressively as “true cancer” and might benefit from lymph node dissection. Unifocal PTMC tumors with diameters equal to or below 0.5 cm may be treated less aggressively. BioMed Central 2019-05-31 /pmc/articles/PMC6543635/ /pubmed/31146753 http://dx.doi.org/10.1186/s12957-019-1638-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Kaliszewski, Krzysztof Diakowska, Dorota Wojtczak, Beata Forkasiewicz, Zdzisław Pupka, Dominika Nowak, Łukasz Rudnicki, Jerzy Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
title | Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
title_full | Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
title_fullStr | Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
title_full_unstemmed | Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
title_short | Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
title_sort | which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543635/ https://www.ncbi.nlm.nih.gov/pubmed/31146753 http://dx.doi.org/10.1186/s12957-019-1638-0 |
work_keys_str_mv | AT kaliszewskikrzysztof whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer AT diakowskadorota whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer AT wojtczakbeata whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer AT forkasiewiczzdzisław whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer AT pupkadominika whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer AT nowakłukasz whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer AT rudnickijerzy whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer |